NAVAMEDIC ASA
Sector unknown·NAVA · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
GLP-1 and obesity treatment
Technology
Market
“In our Prescription Drug (Rx) business, we are making strong progress with Flexilev®. The License and Supply Agreement signed with Orion Corporation in June marks a pivotal milestone. We are now diligently preparing for the commercial launch of Flexilev® in OraFID® across the Nordic countries in 2025. This novel treatment for Parkinson's disease, coupled with a unique dispenser, promises to improve patient outcomes.”
Annual report 2024A · The company itself
Market
“Obesity management is another critical area of focus. Our currently largest product, Mysimba, continues to keep a solid position in Norway despite increased competition. We are committed to expanding our presence in the weight-loss drug market, underscored by initiatives such as The Norwegian Obesity Report 2025, including an educational seminar in Oslo early 2025.”
Annual report 2024A · The company itself
Chains in: US drug pricing policy weakens
Chains out: this mixed effect Healthcare and hospitals
Licensing and partnership deals in pharma
End markets
StrategyPositive impact: strengthens
“Over the last 2-3 years, and particularly after the acquisitions of Impolin AB and Sensidose AB, Navamedic has moved into a position of increased ownership of products and therefore outlicensing and market expansion has become an additional focus area of the strategy. While 2024 showed slower growth than the previous two years, it was a year of significant investments in future growth initiatives and Navamedic fully expects to reach the growth targets going forward, delivering on its growth strategy through increasing revenues both from the existing portfolio of products, out-licensing existing products, and acquiring new product licenses and companies.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“The Company also strives to build and retain value through further ownership and in-licensing as well as further development of assets, both short- and long-term. Through attaining new licensing rights and acquiring new products, the Company will increase the share of pharmaceuticals it owns the marketing rights and trademarks to.”
Annual report 2024A · The company itself
Healthcare and hospitals
End markets
Market
“• In 2024, Navamedic increased its revenues by 3.8% to NOK 531.4 million (NOK 512.0 million) • EBITDA was NOK 46.6 million, compared to NOK 35.5 million in 2023 • Navamedic entered into a License & Supply Agreement with Orion Corporation to market and sell Flexilev® and the OrdFID® dispenser across Europe • Navamedic secured two significant Nordic tenders for the antibiotic portfolio.”
Annual report 2024A · The company itself
Chains in: Ageing population strengthens, GLP-1 and obesity treatment mixed effect
M&A and consolidation
Macro
StrategyPositive impact: strengthens
“With a solid pipeline for future growth, we are committed to continuous business development and selective mergers and acquisitions to drive additional growth.”
Annual report 2024A · The company itself
Contract manufacturers as a business (EMS, CMO, CRO)
End markets
InputNegative impact: weakens
“The Company is dependent on production and delivery of products from its third-party product suppliers. The Company has supply- and distribution agreements with suppliers in which the term of the agreement vary from one to eight years. The Company is dependent on renewing these agreements at fair prices and on market terms and conditions and is therefore in continuous dialogue with the key suppliers to ensure they are renewed at competitive terms.”
Annual report 2024A · The company itself
Chains in: Biotech and drug development strengthens
Geopolitical uncertainty
Macro
DriverNegative impact: weakens
“Navamedic is, like most other companies, exposed to adverse developments in the geo-political situation. Imbalances and/or disruption in global markets may pose a risk to Navamedic’s on-going business to the extent that our suppliers, production partners or other partners may not be able to uphold their production or deliveries. It may also lead to increased transportation costs which may in turn negatively affect Navamedic’s margins.”
Annual report 2024A · The company itself
Chains out: this strengthens Defence budgets, strengthens Energy security, strengthens Tariffs and trade policy, weakens Global trade volumes, strengthens Sea freight and freight rates, weakens Reconstruction of Ukraine
Patent expiry and generic competition
Regulation
DriverNegative impact: weakens
“There is a risk that some of the Company's products may face competition from new products as well as generic products. This risk may be reduced by having a more diversified portfolio of products as well as a broader geographical footprint, and Navamedic is continuously exploring ways to expand its portfolio and extending its geographical present.”
Annual report 2024A · The company itself
Chains out: this weakens Biotech and drug development
Europe
Geography
Geography
“Our expansion in Sweden and Finland is particularly noteworthy, as Sweden approaches the scale of our Norwegian operations— reflecting a promising trajectory.”
Annual report 2024A · The company itself
Geography
“Navamedic sees significant scalability potential in adding new products in the existing distribution and market access platform in the Nordic region and the Benelux countries. With a well-functioning system of logistics and distribution, as well as skilled product specialists who regularly meet with hospitals, specialists, general practitioners and pharmacies, Navamedic has the set-up to launch new prescription and non-prescription pharmaceuticals both in its core geographic areas and potentially expand certain products into new geographical areas.”
Annual report 2024A · The company itself
Nordics
Geography
Geography
“We are now diligently preparing for the commercial launch of Flexilev® in OraFID® across the Nordic countries in 2025.”
Annual report 2024A · The company itself
Geography
“Navamedic sees significant scalability potential in adding new products in the existing distribution and market access platform in the Nordic region and the Benelux countries. With a well-functioning system of logistics and distribution, as well as skilled product specialists who regularly meet with hospitals, specialists, general practitioners and pharmacies, Navamedic has the set-up to launch new prescription and non-prescription pharmaceuticals both in its core geographic areas and potentially expand certain products into new geographical areas.”
Annual report 2024A · The company itself
Sea freight and freight rates
Raw materials and inputs
InputNegative impact: weakens
“It may also lead to increased transportation costs which may in turn negatively affect Navamedic’s margins.”
Annual report 2024A · The company itself
Chains in: Geopolitical uncertainty strengthens
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0.53 bn NOK |
| Revenue growth vs. the year before, same method | 3.8 % |
| EBITDA reported by the company | 0.05 bn NOK |
| Net debt debt incl. leasing minus cash | 0.08 bn NOK |
| Diluted EPS per share | -0.314 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✗ |
| Growing | ✓ |
| Healthy balance sheet | ✓ |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.